Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter

NCT01857323 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor.

NCT NCT01857323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01857323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
September 30, 2013
Enrollment
317 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic obstructive pulmonary disease (copd)